Skip to content
Review Open access

Phytochemical-mediated targeting of signaling pathways in glioblastoma: preclinical evidence, translational potential, and emerging nano-based therapeutic approaches.

Sep 2026 · The Journal of pharmacy and pharmacology · Vol 78 9 · 0 citations
Medicine

TL;DR

Overall, phytochemical modulation of signaling pathways paired with nano-based drug delivery shows potential for enhancing treatment efficacy in GBM.

Abstract

Objectives

Glioblastoma (GBM) is a highly aggressive brain cancer characterized by rapid growth, extensive infiltration, significant molecular diversity, and notable resistance to standard treatments, resulting in a poor prognosis for patients. This emphasizes the necessity for innovative therapeutic strategies based on novel mechanisms. KEY

Findings

GBM tumorigenesis, glioma stem cell maintenance, immunological evasion, and treatment resistance are significantly influenced by the abnormal activation of various oncogenic signaling pathways, such as PI3K/Akt/mTOR, JAK/STAT, NF-κB, MAPK, Wnt/β-catenin, and receptor tyrosine kinases like EGFR and Axl. Phytochemicals such as quercetin, curcumin, resveratrol, and epigallocatechin gallate influence crucial signaling pathways in GBM by inhibiting specific pathways, inducing apoptosis and autophagy, suppressing glioma stemness, and modifying the tumor microenvironment. Furthermore, nano-based delivery systems such as dendrimers, lipid-based nanocarriers, polymeric nanoparticles, and biomimetic exosome-inspired systems enhance stability, bioavailability, and targeted delivery, thereby improving therapeutic efficacy. SUMMARY This review i) explores the potential of phytochemicals in targeting these pathways, ii) summarizes current evidence on phytochemicalmediated modulation of dysregulated signaling pathways in GBM, and iii) highlights emerging nanobased delivery strategies to improve therapeutic efficacy. Overall, phytochemical modulation of signaling pathways paired with nano-based drug delivery shows potential for enhancing treatment efficacy in GBM.

Read PDF

Similar papers

Review Open access Aug 2026

Natural Compounds Targeting Oncogenic Signaling Networks in Glioblastoma: Molecular Mechanisms, Translational Advances, and Clinical Perspectives

The use of molecular diagnostics, including biomarkers, genetic profiling, and advanced imaging, has significantly improved early identification and patient stratification, and the combination of natural compounds shows potential for creating safe, effective, and pathway‐specific treatments for GBM.

Mehrukh Zehravi, Md Abul Hassan, Md. Al Amin et al. · 0 citations
Review Sep 2026

Natural Polyphenols in Glioblastoma: A Multifaceted Approach to Targeting Tumor Progression.

Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with a median survival of less than two years despite surgery, radiotherapy, and temozolomide. Its poor outcome reflects diffuse invasion, cellular heterogeneity, and the activation of overlapping pathways (PI3K/AKT/mTOR, Wnt/β-catenin,...

F. A. Jaber · 0 citations
Review Open access Aug 2026

Phytochemicals as Multitarget Therapeutics in Pancreatic Cancer: Mechanisms, Clinical Evidence, and Translational Challenges

This review demonstrates the therapeutic potential of phytochemicals as multitarget agents in pancreatic cancer, emphasizing their molecular mechanisms, pharmacological properties, and translational relevance.

Md. Rezaul Islam, Abdur Rauf, F. Shourav et al. · 0 citations
Review Open access Aug 2026

Pathway dysregulation and therapeutic resistance in glioblastoma: molecular mechanisms and emerging therapeutic targets

A narrative review summarizes the major signaling pathways implicated in GBM pathogenesis, including EGFR, PI3K/AKT/mTOR, Wnt, and TGF-β signaling, while also discussing emerging therapeutic targets such as FGFR3–TACC3 fusions, regorafenib, and natural killer cell-based immunotherapy.

William Li, Jia-Ming Chen, Yi-Chao Ma · 0 citations
Review Open access Aug 2026

Natural and Synthetic Compounds, Swords for Glioblastoma Therapy: From Tumor to Its Microenvironment

Future studies should prioritize molecularly informed patient stratification, rational combination strategies, and advanced nanocarrier-mediated delivery platforms to facilitate the clinical translation of small-molecule therapeutics for GBM.

Bing-Xia Huang, Yan Wang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.